• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A method for preparing polypeptides in bacteria with an alanine rather than a methionine at the N-terminus. The DNA sequence expressed has an alanine codon immediately following from one to about three contiguous methionine codons including a translation start signal and allows for the expression of polypeptides having the amino acid sequence of, for example, naturally occurring eucaryotic proteins such as various bovine and porcine somatotropin species.
    公开号:SU1646489A3
    申请号:SU4027045
    申请日:1986-02-21
    公开日:1991-04-30
    发明作者:Грабовский Криви Гвен
    申请人:Монсанто Компани (Фирма)；
    IPC主号:
    专利说明:

    (21) 4027045/13
    (22) 21002086
    (31) 704362
    (32) 05.22.85
    (33) US
    (46) 04.30.91. Bul0 number 16
    (71) Monsanto Company (US)
    (72) Gwen Grabowski Krivi (US)
    (53) 575.224 „2: 577„ 2 (048) (088.8)
    (56) Proc. Natl Acac, Sci. USA, 81, p. 5403-5407.
    (54) METHOD FOR OBTAINING BULLY HORMONE GROWTH
    (57) The invention relates to genetic engineering and concerns the production of recombinant bovine growth hormone. The purpose of the invention is to increase the biological activity of bovine growth hormone in relation to the stimulation of lactation in cows. Bovine growth hormone is obtained by constructing recombinant plasmid LNA coding for bovine growth hormone by isolating DNA from plasmid pGHex-I, inserting a codon for alanine following the ATG codon, recloning into plasmid pBGFex-I, transforming the obtained E. coli DNA with subsequent isolation. and purification of the final product. 1 hp f-ly, 3 tab.
    at &
    The invention relates to genetic engineering and concerns the production of recombinant bovine growth hormone.
    The purpose of the invention is to increase the biological activity of bovine growth hormone in relation to the stimulation of lactation in cows
    Bovine growth hormone is obtained by constructing recombinant shtazmidnaya DNA encoding bovine growth hormone, by isolating cDNA from plasmid pGHex-I, inserting a codon for alanine following the ATG codon, by recloning into plasmid GHex-I, transforming the recombinant DNA strains obtained by E. so-li with the subsequent isolation and purification of the final product
    Example 1
    a) Encoding somatotropin, i.e. The 6GR (L) DNA sequence was isolated from pGHex-I as a fragment of Hwa and cloned into the Hwa site of the modified vector Ml3mp8 (M13mp8 / / Hwa). Hwa cuts the coding for 6GR (L) DNA sequence at both ends, thus cutting out the complete coding 6GR (L) sequence. Plasmid pBGHeJ (-I after treatment with Lerment I is mixed in the presence of T4 DNA ligase with RF DNA (RF - Replicative Vector Shape) M13tr8 / Hwa1, linearized with Hwa restriction endonuclease, and treated with alkaline BiosLatase from calf intestine (large horned cattle). The mixture is then incubated overnight at
    ZE
    C & -U
    00

    s
    14 C. Treatment with alkaline dusfatase from the calf intestine (cattle) prevents the recirculation of the vector M13tr8 / Hwa1. The insertion of the coding 6GR (L) DNA sequence into the vector M13tp8 / Hwa1 to form the recombinant vector M13mp8 / BGHex-I is initially controlled by the formation of colorless plaques on the IM101 E. bacterial culture grown on 1 x UT medium using the coating procedure soft agar, which contains 10 ml of 100 mM IHTG (isopropyl - ($ - B-thiogalactopyranoside) and 50 µl of 2% (w / v) X-GAL (5-bromo-4-chloro-3-indolyl-y -B-galactopyranoside) in 3 ml of upper agar, and transfection with the above-mentioned recombinant vector is carried out as described in the insert 6TP (L sequences are confirmed by restriction of isolated RF DNA of the recombinant vector with the enzyme Hwa1, resulting in a Fragment of 590 base pairs, containing the inserted sequence Fragment of 590 base pairs identified by agar gel electrophoresis in 1% agar. All subsequent fragments after treatment with enzymes, it is identified using this procedure. The orientation of the inserted 6GR (L) coding sequences is controlled using RF processing of the recombinant vector with the Smal and Find III enzymes. If the coding sequences are in the correct orientation orientation, a fragment of 207 base pairs is obtained by restriction enzymes. Isolation of the single-stranded (OH) phage DNA is performed, the MISmpS / BGHg-I vector is used as a template for site-specific mutagenesis.
    An oligonucleotide primer containing the sequence for the desired mutation is used to seed the synthesis of a copy of the closed circular DNA of the M13mp8 / BGHex-I cDNA template. The thus-obtained closed ring molecules of double-stranded (DN) DNA are separated from incomplete rings and cDNA rings by centrifuging with an alkaline sucrose gradient. The closed ring dDNNA molecules are used to transform
    0, - about 5
    Q
    five
    E. coli IM101 and the resulting colorless plaques are placed on Pall filters and screened, and hybridization is controlled into the P-labeled form of the oligonucleotide primer used for site-specific mutagenesis. The filters are washed at increasing temperatures until the radioactively labeled signal disappears from the control filter, which is prepared using phage M13pr8 / / BGHgj-I. The filters were washed at room temperature at 6 x SSC (0.9 M NaCl 0.09 M sodium citrate) for 10 minutes, then at 50 ° C at 6 X SSC for 5 minutes, and subsequent washings with increasing temperature at 5 ° C. Plaques that hybridize with the formation of a radiolabelled oligonucleotide primer at temperatures higher than the control phages are considered to be carriers of the newly created 6GR (L, L) coding sequence and are called positive. Separate colorless plaques are taken from the culture of transformed IM101 E. coli cells and grown in 5 ml of medium 2 UT Јl, 6% (w / v) tryptone, 1.0% (w / o) yeast extract, 0.5% ( w / v) NaCl j overnight at 37 ° C under aeration conditions. The phage DNA is then spotted on nitrocellulose, hybridized with a seed labeled with a radioactive element, and washed with increasing temperature, as described above. Phage DNAs that had a hybridization temperature above the M13mp8 / BGHex-I control plaques are potentially positive.
    Potentially positive plaques from both procedures are grown and used to obtain phage cDNA, analyze the cDNA sequence to confirm that it actually carries the 6GR (A, L) coding sequence. The RF DNA M13tr8 / / BGHex-I (ala) is also analyzed and selected using the restriction enzyme analysis of Haye III in order to ensure that the alanine codon is attached after the complex of signals of the onset of the methionine ATS codon, as additional site-constraints are generated Hae III, codon attachment frequency
    Alanine constitutes approximately 2% of the 6GR (L) coding DNA sequence.
    b (The design of the coding 6GR (A, B) DNA sequence; the selection and analysis of the sequence is carried out in the same way as described, but the matrix
    DNA performance. Then, the transformed E. coli IM101 is grown on 1 UT medium containing colorimetric reagents, and the selection is made according to the formation of colorless plaques as described.
    The insertion of cGH (P) coding after M13mp8 / BGHex-I (ala) is followed, and the DNA oligon sequence is confirmed by the selective acid primer listed in Table. 1 The frequency of conversion of a leucine codon into a codon shaft is approximately 10%.
    In tab. Figure 1 shows the design of coding somatotropin with K-terminal alanine sequences.
    c) The design of the coding 6GR (B) DNA sequence, the selection and analysis of the sequence are carried out as described. In this case, the matrix is M13mp8 / BGF-I, and the oligonucleotide primer is used the same as in the design of 6GR (A, B). The frequency of conversion of a leucine codon to a valine codon is about 10%.
    Oligonucleotide site-specific mutagenesis is used to attach the alanine codon to the cGF (F) coding DNA sequence.
    The cGF (F) coding DNA sequence of 590 base pairs, which is contained on the PPGHex-I plasmid, is isolated from this plasmid using the EcoRI and Hind III eudonuclease section, which cut the plasmid at the 5th and 3 ends of the cGH (F) coding sequence. The dissected plasmid pPGHex I is mixed with M13 tr9 DNA in RF, which is cut with EcoRI and Hind III endonucleases and pretreated with alkaline phosphatase from the calf intestine (cattle) in order to prevent repeated ligation of M13 restriction fragments. T4 DNA ligase is then added to the mixture. Due to the presence of abnormally end-to-end phage DNA and gGH (F) DNA sequences formed using two different restriction enzymes, pGH (F) DNA is selectively inserted into the RF phage DNA in the correct 51 orientations. The transformation of E. coli IM101 is then carried out in accordance with the description given above for M13mp8 / BGHX I, using the recombinant vector M13mp9 / PGHex-I, carrying the cP5 (c)
    20
    25
    thirty
    blowing way. Colorless plaques are selected, and the RF DNAs M13xr9 / PCNex-1 are cut with the endonucleases EcoRI and Hind III and subjected to electrophoresis on an agar gel, resulting in a J5 fragment of 590 base pairs containing the inserted DNA with GF (F) 0 Tate M13mp9 phage / PGHex-I was propagated in E0co li III, and onPNA of the phage was isolated.
    DNA Ml3mp9 / PGRex-I is used as a template for site-specific mutagenesis, as described above, to construct the 6GR (A, L) coding sequence using a special seed (Table 1), the frequency of attachment of the alanine codon, in this case PSS, to the cGF (F) coding sequence is about 12%. Preparation of the cGF (A) coding sequence will confirm DNA sequence analysis.
    Example2. Three polypeptides, somatotropins of species 6GR (A, L), 6GR (A, B) and sGR (A) are obtained.
    Coding 6GR (A, L), 6GR (A, B) 3 and 6GR (B) DIC sequences contained on recombinant vectors Mi3mp8 / BGHex-I (ala), M13tpr8 / VONe 1-1. (ala, val) and M13xp8 / / BGPe} C-I (val), respectively, are used to replace the 6GR (L) coding DNA sequence contained on the expression plasmid pBGH x-1. This is accomplished by digesting the corresponding RF DNA M13 45 with the enzyme Xa1. Glasmid expression of pBGFex-I is digested with endonuclease Hwa1, and then treated with alkaline phosphatase from the calf intestine (cattle) in order to prevent re-ligation of restriction fragments. Each of the digested RF DNA was mixed with pVOKech-1 transfected DNA and ligated overnight at 14 ° C. . The recombinant expression vectors thus obtained, which represent pMOM 3209, pMON 3215 and pMOK 3214, carry the coding 6GR (A, L), and bg (B) sequences 40
    50
    55
    DNA performance. Then, the transformed E. coli IM101 is grown on 1 UT medium containing colorimetric reagents, and the selection is made according to the formation of colorless plaques as described.
    The insertion of DNA sequence sequences encoding pGF (F) is confirmed by the following
    0
    five
    0
    blowing way. Colorless plaques are selected, and the M13chp9 / PCNech-1 RF DNA is dissected with the EcoRI and Hind III endonucleases and subjected to agar gel electrophoresis, resulting in a 5 fragment of 590 base pairs containing the inserted DNA with GF (F) 0 Then Phage M13mp9 / PGHex-I are propagated in E0 Coli III, and onPNA of the phage is isolated.
    The Ml3mp9 / PGRex-I DNA is used in i as a template for site-specific mutagenesis, as described above, to construct the 6GR (A, L) coding sequence using a special seed (Table 1). The frequency of attachment of the alanine codon, in this case PSS, to the cGF (F) coding sequence, it is about 12%. Preparation of the cGF (A) coding sequence will confirm DNA sequence analysis.
    Example2. Three polypeptides, somatotropins of species 6GR (A, L), 6GR (A, B) and sGR (A) are obtained.
    Coding 6GR (A, L), 6GR (A, B) and 6GR (B) DIC sequences contained on recombinant vectors Mi3mp8 / BGHex-I (ala), M13tpr8 / VONe 1-1. (ala, val) and M13xp8 / / BGPe} C-I (val), respectively, are used to replace the coding 6GR (L) DNA sequence contained on the expression plasmid pBGH x-1. This is accomplished by digesting the corresponding RF DNA with M13 5 with Xba1 enzyme. Glasmid expression of pBGFex-I is digested with endonuclease Hwa1, and then treated with alkaline phosphatase from the calf intestine (cattle) in order to prevent re-ligation of restriction fragments. Each of the digested RF DNA was mixed with pVOKech-1 transfected DNA and ligated overnight at 14 ° C. . The recombinant expression vectors thus obtained, which are pMOM 3209, pMON 3215 and pMOK 3214, carry the coding 6GR (A, L),) and bg (B) sequence
    0
    five
    These DNAs are appropriate. Then E. coli W 3110 is transformed with a mixture containing pMON 3209 or pMON 3215, or pMON 3214, or pBGFex-I, and grown in Lauria broth (BL) containing 1% (w / v) tryptone, 0.5% (w / v) yeast extract and 0.5% (w / v) NaCl, as well as 12.5 μg / ml tetracycline and 200 μg / ml ampicillin. The E. coli strain W 3110 with the plasmid pMON 3209 was deposited with the ATCC number 53024 ,, The E. coli W 3110 strain with the plasmid pMON 3215 was deposited with the ATCC number 53022 ' TransLormation was performed as follows. Approximately 50 ml of E. coli W 3110 culture are grown in BL medium to OP600 0.60 "The cells are removed as a tablet and resuspended in 10 ml of buffer A containing 25 mҐ Tris, pH 7.6, and .10 mM NaClc Then the cells taken in tablet form and resuspended in 1 ml of Buber A, to which 14 ml of buffer B containing 25 mM Tris, pH 7.6, 10 mM NaCl, 50 mM CaClz is added, and the suspension is incubated on ice for 30 minutes . The cells are then removed in a durma tablet and resuspended in 3 ml of buffer B. A portion in 0.2 ml of suspended cells is again mixed with 0, t ml of buffer B and 0.1-0.5 μg of recombinant expression vector (pMON 3209 or pMON 3215 , pMON 3214 or VG-Neh-1) and incubated on ice in
    lex
    for 60 minutes. Then the incubated mixture is heated for 1 minute at 37 ° C, after which 3 ml of BL medium are added. Next, the resulting mixture is incubated for 60 min at 37 ° C. The cells are removed in tablet form and resuspended in 300 ml of BL medium and grown on BL plates containing the above antibiotics. Resistant colonies are then selected and the DNAs of the expression vectors pMON 3209, pMON 3215, pBCH-1 and pMOI 3214 are isolated. III / Smal 200 base pairs, confirming the presence of coding 6GR (A, L), 6GR (V) and 6GR (A, B) DNA sequences in the correct orientation Next, the plasmids expression pMON 3209 and pltON 3215 are analyzed using endonuclease analysis
    0
    five
    0
    five
    0
    five
    0
    five
    restriction (Pae III) in order to verify the presence of the new Nae III site formed upon the addition of the GSS (alanine) codon. A 5 Xbp Hwa fragment from the pHON 3209, pMOK 3214 and pMON 3215 vectors was analyzed for sequence composition in order to confirm the expression of encoding for 6GR (A, L), 6GR (E) and 6GR (A, B) in these vectors DNA sequences
    Individual colonies of E. coli W 3110 carrying plasmids pMON 3209, pHON 3214, BOHejt-I or pMON 3215 are placed in 5 ml BL, containing 12.5 μg / ml tetracycline, and grown overnight at 37 ° C with aeration. Then, 0.5 ml of each culture is used for growing separately for 25 ml of M9 medium containing (for 1 l of medium) 100 ml of salts (70 g, 30 g of KNgP04, 5 g of NaCl, 10 g of TP4Cl per 1000 ml of total volume) 1.2 ml of 1 M MgSO. Solution, 0.25 ml of 0.1% B4, 12.5 ml of 20% (w / v) glucose solution, 0.025 ml of 1 M CaCl solution, supplemented with 0.5% (w / v) casamic acids and 6.25 µg / ml tetracycline and contained in a 250 mm flask. Each culture was grown at 37 ° C under aeration conditions until an OP600 (optical density in the 600 nm range) reached x 1.0. Next, 0.2 ml is extracted from each of the mentioned flasks and is individually lysable in the dodecyl sulfate sodium (SDS) buffer of polyacrylamide gel electrophoresis (PAGE) and analyzed by the method of SDS PAGE. The proteins with a molecular weight of 22000 daltons in high concentrations obtained in E. coli W 3110 culture for both genetic constructs, E. coli W 3110 culture cells that carry the pBR322 plasmid do not produce 22,000 dalton protein, which binds to the antisomatotropin antibodies.
    Bacteria carrying plasmids pMON 3209, pMON 3214, rvnneh-1 and pMON 3215 are stored as follows. Each colony of E. coli W 3110 culture transformed with only one plasmid (pMON 3209 or pMSH 3215, pMON 3214 or pBGHex-I) was grown overnight at 37 ° C in 5 ml BL, plus 12.5 μg / ml tetracycline with aeration. A serving of 1 ml each
    After overnight culture, they are added separately to individual flasks containing 25 ml of BL plus 12.5 µg / ml of tetracycline and grown until reaching RATO1.0. The cells from each flask are then collected by centrifugation at an acceleration of 6000 x g at 4 ° C for 5 min. Tablets. Separately, suspend with OV in 12 ml of BL plus 7.5% (w / w) DMSO and very quickly freeze on dry ice in portions in t ml. Next, the cells are stored in a refrigerator with liquid nitrogen. 10 µg of purified plasmid DNA is stored at -80 ° C.
    The cGH encoding (A) sequence containing on the recombinant vector M13mp9 / PGHex-I Cala) is used to replace the 6GR (L) encoding DNA sequence containing on the modified expression vector The modified expression vector pBGHex-if is an ex vector - compression of pBGHe) (- I, in which the restriction site EeoRI located upstream of the tryptophan promoter (ptr p) is removed. The modified expression vector pBGHex-I is constructed by partial digestion with EcoRI pBGHex-I followed by treatment with nuclease SI with in order to remove sticky ends
    pBGHav-I after restriction subjected
    are recycled using
    / T4 DNA ligase, and then used to transform a culture of E. coli JM101. All this is carried out as previously described. Plasmid DNA from each colony was analyzed for the presence of an EcoRI / 5 Hind III fragment of 590 base pairs, carrying the cGF (A) coding sequence, and an EcoRI fragment / / Pst I of 1050 base pairs, carrying the ptr p sequence. The removal of this EcoRI restriction site simplifies the site-specific insertion of a specific site of the cGF (A) coding sequence into the expression vector pBRHex-I in the correct orientation. The recombinant expression vector thus obtained is hereinafter referred to as pMON 3213. A mixture containing pMSH 3213 is used to transform an E. coliW3110 culture, then the transformed cells are grown and subjected to selection: Cul5
    0
    „

    E coli W 3110 tour, containing pMON 3213, was deposited under the ATCC number 53023. Replacing the cGH (L) coding sequence with the cGH (A) coding sequence in the pBGHe expression vector) (- I confirm (confirm with pMON 3213 DNA extraction and subsequent cross section of the said expression vector endonucleazamone EcoRI and Hind III, and a fragment of 590 base pairs is obtained, and a section using Hae III shows the presence of an additional Hae III restriction fragment, which is formed due to the presence of the alanine codon in the cGF (A) coding DNA sequence Final confirmation of the presence of the cGF (A) coding DNA sequence in the expression vector pMSh 3213 is obtained by partial analysis of the sequence of the EcoRI / Hind III fragment of 590 base pairs.
    The expression of the cGH (A) coding DNA sequence and the production of cGH (A) in E. coliW3110 culture were carried out using the same techniques that were previously described and used to obtain 6GR (A, L) and 6GR (A, B). Similarly, high protein concentrations of 22,000 daltons are obtained, which is determined by SDS-PAGE analysis. E. coli W 3110 cells carrying the pMON 3213 expression vector are also stored as previously described and used for production of pGH (A) in large quantities (fermentation is carried out in 10-100-liter containers. ) in a 100 liter fermentation reactor, it is approximately I g / L broth.
    Example The somatotropic polypeptides synthesized in E. coli culture are purified from crude, solubilized light refracting bodies containing one of 6GR (A, L), 6GR (A, B), met-6GR (V), met-6GR (L) or cGH (A) using immunoadsorbent chromatography0 All three types of somatotropin, purified using immunoadsorbent chromatography, had a purity greater than 95%. This fact is established using the LTO-PAGE analysis using 1 mg of purified protein on a 7.5–15% (w / v) gradient gel. Purified Protein Concentrations
    A16
    Dov 6GR is determined using a known assay using high resolution liquid chromatography
    Proteins purified by chromatography based on the principle of an immune agent, for use in an N-terminal sequence assay, are dialyzed until water is completely removed, and then lyophilized. Before performing the analysis of the fr-terminal sequence, the purified proteins are again suspended in bicarbonate buffer. ammonium containing 50 mM ammonium bicarbonate plus 0.1% (w / v) SDS, and dialyzed against the same buffer in order to remove residual tris / oxymethyl / aminomethane / tris / and glycine,
    B tab. 2 shows the results of the analysis of N-terminal sequences for several preparations of polypeptides 6GR (A, L), 6GR (A, B), met-6GR (B), met-6GR (L) and sGR (A). The amount of protein with N-terminal methionine is given as a percentage of the total somatotropin content in the sample. Two methods are used to determine the amount of methionine. Using the indirect method, the amount of NHv-met-ala-pBe ... in the predominant NH2 ala-pheoо population is calculated from differences in the lag-signals. Since this procedure depends on some evaluation of the normal lag for the sequence, which varies from cycle to cycle, it is only a very rough estimate for the containing NH-ala-phe sequence ... Direct method, containing the Edman molecular degradation reaction, is comparing the power of signals from PTH-tnet to PTH-ala after separating PTH-met from chemical noise using high-resolution 1 liquid chromatography (HPLC). In particular, the Edman degradation reaction involves the interaction of the N-terminal amino acid with a reagent that cuts off this amino acid, and its subsequent release in the form of a PTH-derivative of this amino acid. The latter procedure will give good estimates (%) for met-ala-phe ... if the contamination with free amino acid is low.


    five
    0
    five
    489
    .
    0
    five
    0
    five
    0
    eleven
    The degree of N-terminal methionine treatment varies in cells from fermentation to fermentation, but always occurs in at least 80% of all somatotropin molecules.
    Example 40 Table 3 shows the change in milk yield caused by injection of solubilized 6GR species to cows. From the data obtained, it is clear that 6GR (A, B) and met-bGR stimulate milk yield to a much more significant extent than the corresponding (GR containing leucine) analogues (A, L) and met-bGH (L). In addition, the tested valine 6GR-types, when compared with leucine BPR-species, give in a statistical sense (, 02) a more significant increase in milk yield.
    The study is conducted as follows.
    Cows of choletein breed during their second and third trimester lactation give 5 ml of sodium bicarbonate solution (pH 9.8 + 0.5), only (control) or containing about 25 mg of 6GR (A, B), 6GR (A, L) , met - 6GR (V) or met - 6GR (L), hereinafter, all these mixtures are collectively referred to as the subject somatotropins), daily. All tested somatotropins and control samples were administered parenterally by intramuscular injection into the semitendinus muscle daily for 21 days. Every cow's daily milk yield is recorded, six days before the first daily injection and for 21 days, during which the injections were made. Analyze every fat content, protein content in milk and somatic cells. The results presented in Table. 3, indicate that the increase in milk yield obtained by applying 6GR (A, B) to cows is about 50% higher than that obtained using 6GR (A, L) and about 17% higher when using met - 6GR (B ) than when applying met - 6GR (L).
    g
    权利要求:
    Claims (2)
    [1]
    Invention Formula
    A method for producing bovine growth hormone, which includes obtaining cDNA that encodes bovine growth hormone, inserting cDNA into bacteriophage, transforming the obtained recombinant phages of Escherichia coli strains, selecting clones containing recombinant plasmids with the bovine hormone gene, isolating recombinant plasmids, and drawing. into the expression vector with subsequent transformation by the resulting plasmid of expression of E. coli strains, selection of the transformed strains, cultivation in a nutrient medium, isolation and purification to a single product, characterized in that, in order to increase the biological activity of bovine growth hormone in
    pGH (A) 51 CCAGTGMTTCTATGGCCTTCCCAGCTATG M13mp9 / PGHey-I
    Try
     The amount of protein with N-terminal methionine was calculated in percent from the total content of somatotropin in the sample. Data for protein purified after two separate fermentations.
    in relation to cows lactation stimulation, a cDNA fragment isolated from plasmid pGHex-I, using site-specific mutagenesis, insert a codon for alaiin following the ATC codon and the resulting modified fragment is cloned into plasmid pBGHfrj {-I instead of the DNA sequence encoding BGH (L).
    [2]
    2. The method according to claim 1, wherein the bovine hormone is BGH (A, V).
    Table 1
    pMON 3213
    table 2
    N-terminal methionine,%
    Nepr I I Pr my
    one
    Note ,, Values are based on the least squares method (in kilograms) per cow (per day) of milk with a normalized liquid of 3.5% fat.
    Table 3
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1646489A3|1991-04-30|Method for preparation of bovine hormone growth
    JP2882775B2|1999-04-12|Human-glia-derived neurite factor
    US5470719A|1995-11-28|Modified OmpA signal sequence for enhanced secretion of polypeptides
    EP0047600B1|1992-02-26|Bovine pre-growth and growth hormone
    RU2129606C1|1999-04-27|STRAIN ESCHERICHIA COLI JM 105 TRANSFORMED WITH PLASMID PAE12 - PRODUCER OF ALPHA-AMIDATING ENZYME, RECOMBINANT PLASMID PAE12, MURINE CELLULAR LINE C127 TRANSFORMED WITH PLASMID PDBPV-MMTNEO α - PRODUCER OF ALPHA-AMIDATING ENZYME, RECOMBINANT PLASMID PDBPV-MMTNEO α
    JP3207416B2|2001-09-10|Somatotropin and analogs
    DK174927B1|2004-03-01|DNA encoding human factor VIII: C, vector comprising this DNA, transformed host comprising this DNA, and method for producing human factor VIII: C
    US6229003B1|2001-05-08|Production of bovine growth hormone by microorganisms
    US5004692A|1991-04-02|Cloning and expression of phosopholipase C genes
    RU2072393C1|1997-01-27|Method for obtaining recombination polypeptide possessing growth hormone properties
    KR100316347B1|2002-08-27|Recombinant microorganisms expressing a fusion protein of Escherichia coli enterotoxin II signal peptide and fusion protein of human growth hormone and a method of producing human growth hormone using the same
    JPH07108221B2|1995-11-22|Rennin production method
    US5714581A|1998-02-03|Polypeptide derivatives of human granulocyte colony stimulating factor
    WO1990008164A1|1990-07-26|Somatotropin analogs
    US6316004B1|2001-11-13|Chimeric somatostatin containing protein and encoding DNA, plasmids of expression, method for preparing chimeric protein, strain-producers, immunogenic composition, method for increasing the productivity of farm animals
    EP0280407B1|1998-08-05|Process for the production of recombinant polypeptides with porcine growth hormone activity
    KR960016704B1|1996-12-20|Cdna encoding somatotropin, expression vectors and hosts
    US5656596A|1997-08-12|Method of treating lesions in a nervous system
    JP2591713B2|1997-03-19|DNA sequences, recombinant DNA molecules and methods for the production of the enzyme mutarotase from Acinetobacter calcoaceticus
    EP0285361A2|1988-10-05|Purification of apase-1 1 and retrieval of the nematode resistance gene
    DE3220333C2|1987-08-06|
    WO1987001708A2|1987-03-26|Enhanced bioactivity of mammalian somatotropin through selective deamidation
    EP0443790B1|1995-12-13|Growth hormone-like glycoproteins
    CA1302321C|1992-06-02|Preparation of polypeptides
    EP0263206A1|1988-04-13|Enhanced bioactivity of mammalian somatotropin through selective deamidation
    同族专利:
    公开号 | 公开日
    US6210928B1|2001-04-03|
    US4861868A|1989-08-29|
    US5744328A|1998-04-28|
    ZA861323B|1987-02-25|
    US5399489A|1995-03-21|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4056520A|1972-03-31|1977-11-01|Research Corporation|Clinically active bovine growth hormone fraction|
    US3842063A|1971-06-03|1974-10-15|Lilly Co Eli|Polypeptides from bovine,ovine,human and porcine pancreas|
    US4425437A|1979-11-05|1984-01-10|Genentech, Inc.|Microbial polypeptide expression vehicle|
    US4704362A|1977-11-08|1987-11-03|Genentech, Inc.|Recombinant cloning vehicle microbial polypeptide expression|
    US4571421A|1979-11-05|1986-02-18|Genentech, Inc.|Mammalian gene for microbial expression|
    US4366246A|1977-11-08|1982-12-28|Genentech, Inc.|Method for microbial polypeptide expression|
    US4342832A|1979-07-05|1982-08-03|Genentech, Inc.|Method of constructing a replicable cloning vehicle having quasi-synthetic genes|
    US4443539A|1980-02-05|1984-04-17|The Upjohn Company|Process for preparing bovine growth hormone|
    IL59690A|1980-03-24|1983-11-30|Yeda Res & Dev|Production of bovine growth hormone by microorganisms and modified microorganisms adapted to produce it|
    IE52755B1|1980-08-26|1988-02-17|Univ California|Bovine pre-growth and growth hormone|
    SE453510B|1980-12-29|1988-02-08|Toyo Jozo Kk|PEPTIME FOR ANALYSIS OF HUMANT PARATYROID HORMON|
    JPS58996A|1981-06-01|1983-01-06|Torasuteiizu Mishigan Suteeto|Method of cloning ox growth hormone gene in germ|
    US4880910A|1981-09-18|1989-11-14|Genentech, Inc.|Terminal methionyl bovine growth hormone and its use|
    NZ201918A|1981-09-18|1987-04-30|Genentech Inc|N-terminal methionyl analogues of bovine growth hormone|
    EP0085036A1|1982-01-18|1983-08-03|Monsanto Company|Method for improved bovine milk production|
    US4670393A|1982-03-22|1987-06-02|Genentech, Inc.|DNA vectors encoding a novel human growth hormone-variant protein|
    US4423037A|1982-05-13|1983-12-27|The General Hospital Corporation|Inhibitors of peptide hormone action|
    US4745069A|1982-05-25|1988-05-17|Eli Lilly And Company|Cloning vectors for expression of exogenous protein|
    DE3380262D1|1982-05-25|1989-08-31|Lilly Co Eli|Cloning vectors for expression of exogenous protein|
    CA1224432A|1982-08-17|1987-07-21|Gary N. Buell|Dna sequences, recombinant dna molecules andprocesses for producing bovine growth hormone-likepolypeptides in high yield|
    US4673641A|1982-12-16|1987-06-16|Molecular Genetics Research And Development Limited Partnership|Co-aggregate purification of proteins|
    AU2092983A|1982-11-08|1984-05-17|Genentech Inc.|Porcine growth hormone produced by recombinant dna technology|
    EP0111814A3|1982-12-16|1985-08-14|Mgi Pharma, Inc.|The cloning and expression of nucleotide sequences encoding bovine growth hormone|
    GR79124B|1982-12-22|1984-10-02|Genentech Inc|
    US4661454A|1983-02-28|1987-04-28|Collaborative Research, Inc.|GAL1 yeast promoter linked to non galactokinase gene|
    US4755465A|1983-04-25|1988-07-05|Genentech, Inc.|Secretion of correctly processed human growth hormone in E. coli and Pseudomonas|
    BG49718A3|1983-07-15|1992-01-15|Bio Technology General Corp|Method for preparing of polypeptid with superoxiddismutasne activitty|
    US4521409A|1983-10-03|1985-06-04|Cornell Research Foundation, Inc.|Use of growth hormone to enhance ruminant mammary development|
    US4549986A|1983-12-23|1985-10-29|The Salk Institute For Biological Studies|Human CGRP|
    DE3585170D1|1984-03-06|1992-02-27|Lilly Co Eli|EXPRESSION VECTORS FOR BOVINE GROWTH HORMON DERIVATIVES.|
    DE3588249T2|1984-08-16|2004-05-06|Savient Pharmaceuticals, Inc.|Method of producing human growth hormones|
    US4795706A|1985-01-31|1989-01-03|Eli Lilly And Company|Novel expression control sequences|
    US5037806A|1985-02-22|1991-08-06|Monsanto Company|Biologically active method using somatotropins|
    US4861868A|1985-02-22|1989-08-29|Monsanto Company|Production of proteins in procaryotes|US5037806A|1985-02-22|1991-08-06|Monsanto Company|Biologically active method using somatotropins|
    US5141922A|1985-02-22|1992-08-25|Monsanto Company|Biologically active proteins and a method for their use|
    US4861868A|1985-02-22|1989-08-29|Monsanto Company|Production of proteins in procaryotes|
    US5244882A|1987-03-12|1993-09-14|Amgen, Inc.|Porcine growth hormone analogs, and compositions|
    US5104806A|1987-03-12|1992-04-14|Amgen, Inc.|Porcine growth hormone analogs encoding dna|
    EP0649305A1|1992-07-08|1995-04-26|Monsanto Company|Benzimidazoles for alleviating stomach ulcers in swine|
    US5932439A|1995-11-13|1999-08-03|Monsanto Comapny|Escherichia coli K-12 strains for production of recombinant proteins|
    WO2000060103A2|1999-04-01|2000-10-12|Monsanto Technology Llc|Dna construct comprising a cyanophage of cyanobacteria promoter and its use|
    DE19943177C2|1999-09-09|2002-10-24|Dieter Jenne|Process for the production of active series proteases and inactive variants|
    AU3854001A|2000-02-24|2001-09-03|Monsanto Technology Llc|Non-aqueous injectable formulations for extended release of somatotropin|
    AU7149101A|2000-06-26|2002-01-08|Monsanto Technology Llc|Non-aqueous surfactant-containing formulations for extended release of somatotropin|
    US6664234B1|2000-06-30|2003-12-16|Monsanto Technology Llc|Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin|
    US9849188B2|2009-06-08|2017-12-26|Amunix Operating Inc.|Growth hormone polypeptides and methods of making and using same|
    AU2010210618B2|2009-02-03|2014-08-21|Amunix Pharmaceuticals, Inc.|Extended recombinant polypeptides and compositions comprising same|
    US8703717B2|2009-02-03|2014-04-22|Amunix Operating Inc.|Growth hormone polypeptides and methods of making and using same|
    US8680050B2|2009-02-03|2014-03-25|Amunix Operating Inc.|Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same|
    US8133916B1|2009-03-10|2012-03-13|Amelgo, LLC|Control of milk production and mammary involution|
    法律状态:
    2005-05-10| REG| Reference to a code of a succession state|Ref country code: RU Ref legal event code: MM4A Effective date: 20040222 |
    优先权:
    申请号 | 申请日 | 专利标题
    US06/704,362|US4861868A|1985-02-22|1985-02-22|Production of proteins in procaryotes|
    [返回顶部]